Genetically engineered fibroblast growth factor (FGF) can be safely injected into the ischemic limbs of patients with severe vascular disease, according to phase I trial results presented Tuesday at a medical meeting in Miami.
Moreover, such therapy dramatically reduced limb pain and promoted ulcer healing, study author Dr. Anthony Comerota, from the Jobst Vascular Center in Toledo, Ohio, told Reuters Health. Based on these promising findings, he noted that a phase II trial is already in the works.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!